Overview

Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to observe the clinical effect and safety of Recombinant Human Endostatin in non-small cell lung cancer with leptomeningeal metastasis

Phase:

Phase 4

Details

Lead Sponsor:

Hui Bu

Treatments:

Endostatins
Methotrexate